Roni Shouval
@RShouval
Followers
1K
Following
1K
Media
87
Statuses
847
Precision Cellular Therapy | Attending - BMT and Cellular Therapy Service @sloan_kettering
Manhattan, NY
Joined December 2018
🚨 Just out @NatureMedicine!.Introducing InflaMix—a point-of-care tool that identifies an #inflammatory 🔥 signature predictive of #CART failure in #lymphoma.Led by Sandeep Raj (@SSRaj017) 👏@MSKCancerCenter. 🧵Let’s break it down.
3
41
142
RT @moh7madhomod: What is the exact impact of bridging radiation ☢️ (BRT) on CAR T efficacy/safety profile in NHL? . BRT is wildly integrat….
0
7
0
RT @NicoGagelmann: Share your latest breakthroughs at the @COSTEMCongress - the premier meeting for cutting-edge debates in hematopoietic s….
0
5
0
RT @BrianShafferMD: Updated allogeneic stem cell donor guidelines from the CIBMTR/NMDP. A collaborative effort with many wonderful colleagu….
0
4
0
JCI - Clinical, tumor and product features associated with outcomes after axicabtagene ciloleucel therapy in follicular lymphoma
1
4
9
RT @GreenLymphoLab: Lymphoma Microenvironment Archetype Profiles (LymphoMAPs). Just presented by @dgermain21 at #18icml @icmlugano, now ava….
0
29
0
RT @StefanieBailey_: We previously showed that IFNg is required for CAR-T efficacy in solid tumors, but is it always good? Here, we show th….
0
23
0
RT @NicoGagelmann: 🎉Finally out🎉. Remission conversion drives outcomes after CAR T-cell therapy for multiple myeloma. Now in @BloodPortfoli….
0
29
0
Phenomenal work by @thelunar_a. Grateful to @TheIACH for highlighting our study. Read more @BloodCancerJnl.
👂Hear the latest @TheIACH NEWS podcast:. CAR T-cell therapy response varies by extranodal disease site in large B-cell lymphoma.by Dr. Alejandro Luna.⬇️⬇️. @thelunar_a @RShouval @Mohty_EBMT @nagler_EBMT
0
2
7
📢 New Review Out in @Haematologica!.Together with Ofrat Beyar Katz and @KRejeski, we discuss hematologic toxicities of CAR-T therapy—definitions, mechanisms, and clinical impact. Read the full review 👉 #CAR_T #Hematology #Toxicity
0
9
34
RT @SantoshVardhana: Combined #preprint and paper alert! Together with @SohrabShah and @VStrongMD, we have been exploring a fundamental pa….
0
13
0
RT @GomezDLeonMD: 🚨New milestone for #CARTcell therapy in #GlobalHematology!.We report the first successful decentralized, academic-grade C….
0
30
0
RT @MSK_DeptOfMed: Congrats to @KRejeski, @RShouval, and their team on developing a new grading system to evaluate patterns of thrombocytop….
0
5
0
🚨 Check out our new grading system for thrombocytopenia (#T_ICAHT) after #CART @BloodJournal .Led by Drs. @KRejeski, Jaime Sanz, @StatFei & team — incredible multicenter collaborative effort. See Kai’s 🧵for more insights!.
One of the more frequent questions we’ve received since the development of the ICAHT grading system is:. What about thrombocytopenia after CAR T-cell therapy?. We’ve tackled this question head-on in our new paper out now in @BloodJournal 👇.
0
5
20
RT @romeerizwan: Excited to share our review on CAR arming of the innate immune cells. Engineering innate immune cells for cancer immunothe….
0
21
0
8/ Huge thanks to @MSKBiostats’ Sean Devlin for leading the statistical analyses, and to @thelunar_a for his tremendous dedication to this work. #CAR_T #LBCL #Immunotherapy #Lymphoma #HemeOnc.
0
0
1
7/ Our study highlights the need to consider disease location in CAR-T for LBCL. Patients with high-risk EN sites may benefit from tailored strategies—like site-directed #radiotherapy—to improve outcomes.
1
0
0
6/ Among patients who relapsed after CAR-T, outcomes varied by site. Those with nodal-only relapse had 64% 2-year OS, compared to 25% with mixed EN + nodal and 23% with exclusive EN relapse. EN relapse was associated with markedly worse survival.
1
0
0